ReviewJournal of neurochemistry2008
Angiotensin-converting enzyme 2 in the brain: properties and future directions.
Review in Journal of neurochemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 3 syntheses or guidelines pooled it, 326 citations in OpenAlex.
- Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.Hypertension (Dallas, Tex. : 1979) · 2021Pooled it
- What can the neurological manifestations of COVID-19 tell us: a meta-analysis.Journal of translational medicine · 2021Pooled it
- Central nervous system manifestations in COVID-19 patients: A systematic review and meta-analysis.Brain and behavior · 2021Pooled it
- Angiotensin‑converting enzyme 2 expression in human tumors: Implications for prognosis and therapy (Review).Oncology reports · 2025Review
- Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine.Current neuropharmacology · 2025Review
- Review
- CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.CNS drugs · 2024Review
- Semi-Automatic Analysis of Specific Electroencephalographic Patterns during NREM2 Sleep in a Pediatric Population after SARS-CoV-2 Infection.Journal of personalized medicine · 2024Article
- Role of Inflammation in the Development of COVID-19 to Parkinson's Disease.Journal of inflammation research · 2024Article
- Review
- Neurological complications and effects of COVID-19: Symptoms and conceivable mechanisms.Brain hemorrhages · 2023Review
- COVID-19 in the nervous system: physiopathology and neurological manifestations.Arquivos de neuro-psiquiatria · 2023Review
- COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments.Non-coding RNA research · 2023Review
- From Cell to Symptoms: The Role of SARS-CoV-2 Cytopathic Effects in the Pathogenesis of COVID-19 and Long COVID.International journal of molecular sciences · 2023Review
- Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination: From the National MS Society Case Conference Proceedings.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Mechanisms of gastrointestinal barrier dysfunction in COVID-19 patients.World journal of gastroenterology · 2023Review
- Central angiotensin 1-7 triggers brown fat thermogenesis.Physiological reports · 2023Article
- Exploring the Role of ACE2 as a Connecting Link between COVID-19 and Parkinson's Disease.Life (Basel, Switzerland) · 2023Review
- Coronavirus Disease: Subacute to Chronic Neuroimaging Findings.Neuroimaging clinics of North America · 2023Review
- Brain Renin-Angiotensin System: From Physiology to Pathology in Neuronal Complications Induced by SARS-CoV-2.Analytical cellular pathology (Amsterdam) · 2023Review
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Angiotensin (Ang)-converting enzyme (ACE) 2 cleaves Ang-II into the vasodilator peptide Ang-(1-7), thus acting as a pivotal element in balancing the local effects of these peptides. ACE2 has been identified in various tissues and is supposed to be a modulator of cardiovascular function. Decreases in ACE2 expression and activity have been reported in models of hypertension, heart failure, atherosclerosis, diabetic nephropathy and others. In addition, the expression level and/or activity are affected by other renin-angiotensin system components (e.g., ACE and AT1 receptors). Local inhibition or global deletion of brain ACE2 induces a reduction in baroreflex sensitivity. Moreover, ACE2-null mice have been shown to exhibit either blood pressure or cardiac dysfunction phenotypes. On the other hand, over-expression of ACE2 exerts protective effects in local tissues, including the brain. In this review, we will first summarize the major findings linking ACE2 to cardiovascular function in the periphery then focus on recent discoveries related to ACE2 in the CNS. Finally, we will unveil new tools designed to address the importance of central ACE2 in various diseases, and discuss the potential for this carboxypeptidase as a new target in the treatment of hypertension and other cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.